Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer

Trial Details

NCT ID

NCT06427239

Phase

PHASE1 / PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• HRS-4642
• Adebrelimab

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Patients volunteered to participate in this study and signed informed consent;
• Age: ≥18 and ≤75 years old, male or female;
• Advanced (metastatic or unresectable) Pancreatic ductal adenocarcinoma; and subjects must have at least one measurable lesion as defined by RECIST …
• With failure or absence of standard treatment, and progress within 6 months of adjuvant therapy can also be included in the study;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.